Boston Scientific Reports Q3 2026 Results and Issues Q4 Guidance

Executive Overview

On October 28, 2026, Boston Scientific Corporation furnished a Current Report on Form 8-K under Item 2.02 (Results of Operations and Financial Condition) and Item 9.01 (Financial Statements and Exhibits), detailing its financial results for the third quarter ended September 30, 2026.

Key Financial Highlights

• Net Sales: Reached $5.138 billion, up 1.5% compared to $5.065 billion in Q3 2025 on reported, operational, and organic bases.
• GAAP Diluted EPS: $0.40, down from $0.51 in the prior-year period.
• Adjusted EPS: $0.73, down slightly from $0.75 in Q3 2025.
• Operating Challenges: Management highlighted operations restoration efforts following a cybersecurity incident experienced during the year.

Segment & Regional Performance

• Cardiovascular: $3.406 billion net sales, up 1.9% YoY.
• MedSurg: $1.733 billion net sales, up 0.6% YoY (0.7% organic).
  • Endoscopy: $741 million (-0.8% reported; -0.6% organic)
  • Urology: $661 million (-3.2% reported; -3.1% organic)
  • Neuromodulation: $331 million (+13.1% reported; +13.0% organic)
• Geographic Breakdown:
  • United States: $3.309 billion (+0.5%)
  • EMEA: $829 million (+4.4% reported; +6.1% operational)
  • APAC: $797 million (-0.6% reported; -1.1% operational)
  • LACA: $203 million (+16.0% reported; +10.5% operational)

Guidance Update

• Full-Year 2026 Outlook:
  • Reported net sales growth of approximately 4.25% (organic ~3.75%).
  • Adjusted EPS expected between $3.16 and $3.18.
• Fourth Quarter 2026 Outlook:
  • Reported and organic net sales growth projected to be (3.0)% to (1.0)% YoY.
  • Adjusted EPS projected between $0.77 and $0.79.